| The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. | |
| | |
MedLine Citation:
|
PMID: 20303574 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: To study the effect of zoledronic acid on patients with pre-existing osteoporosis on androgen deprivation therapy (ADT), who are at highest risk for fracture. Zoledronic acid is a potent bisphosphonate that can prevent osteoporosis in patients with nonmetastatic (M0), prostate cancer (CaP) who are initiating ADT. The effect of zoledronic acid on patients with pre-existing osteoporosis on ADT, who are highest risk for fracture, has not been adequately studied. METHODS: We enrolled 28 patients with M0 CaP on ADT with severe osteopenia or osteoporosis (baseline bone-mineral density (BMD) T score < -2.0) in this open-label, single-arm trial to assess the effect of zoledronic acid on BMD. All patients also received supplemental calcium and vitamin D, and were counseled about lifestyle modifications. Patients received zoledronic acid (4 mg) intravenously every 3 months for 4 treatments. BMD was measured by dual energy X-ray absorptiometry scan at enrollment, 6 and 12 months. Primary endpoint was percent change in lumbar spine BMD. RESULTS: This was a high-risk patient population-primarily older Caucasians (mean age, 73 years), former smokers, and moderate users of alcohol. Mean duration of ADT was 2.4 years. Pre-existing osteopenia or osteoporosis was observed in a single site in 9 patients and multiple sites in 19 (68%). After 12 months of zoledronic acid, lumbar spine BMD increased 4.17% (P < .0001), and BMD increased significantly (P < .05) in both hips and the right femoral neck. Seven patients (25%) experienced improved BMD into the nonosteoporotic range (T score > -2.0). Zoledronic acid infusion was well tolerated and without substantial renal toxicity. CONCLUSIONS: Zoledronic acid improves BMD in men with M0 CaP on ADT with severe osteopenia or osteoporosis (T scores < 2.0). This novel finding identifies a high-risk patient population that can potentially benefit from bisphosphonate therapy. |
| | |
Authors:
|
Steven C Campbell; Nirmala Bhoopalam; Thomas E Moritz; Mona Pandya; Padmini Iyer; Peter Vanveldhuizen; Nancy K Ellis; Lizy Thottapurathu; Harinder Garewal; Stuart R Warren; Nicholas Friedman; Domenic J Reda |
Related Documents
:
|
20346254 - Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile d... 7586604 - Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women? 20147814 - Ctx biochemical marker of bone metabolism. is it a reliable predictor of bisphosphonate... 8896064 - Follow-up study of biological parameters in elderly institutionalized patients more tha... 21763014 - Relationship between changes of body mass index (bmi) and cognitive decline in parkinso... 10955334 - Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate? |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't Date: 2010-03-19 |
Journal Detail:
|
Title: Urology Volume: 75 ISSN: 1527-9995 ISO Abbreviation: Urology Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-05-10 Completed Date: 2010-06-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0366151 Medline TA: Urology Country: United States |
Other Details:
|
Languages: eng Pagination: 1138-43 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Edward Hines Jr VA Hospital, Hines, Illinois, USA. campbes3@ccf.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Androgen Antagonists / therapeutic use Bone Density Conservation Agents / therapeutic use* Bone Diseases, Metabolic / etiology, prevention & control* Diphosphonates / therapeutic use* Gonadotropin-Releasing Hormone / analogs & derivatives Humans Imidazoles / therapeutic use* Male Orchiectomy Osteoporosis / etiology, prevention & control* Prostatic Neoplasms / therapy* Severity of Illness Index |
| Chemical | |
Reg. No./Substance:
|
0/Androgen Antagonists; 0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 118072-93-8/zoledronic acid; 33515-09-2/Gonadotropin-Releasing Hormone |
| Comments/Corrections | |
Comment In:
|
Urology. 2010 May;75(5):1143
[PMID:
20451736
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Estrogenic and AhR activities in dissolved phase and suspended solids from wastewater treatment plan...
Next Document: A survey of primary care physician practices in the diagnosis and management of women with interstit...